• Antimycin A4: A Two-Axis Assay Strategy

  2026-08-19

  Antimycin A4 is both an ATP-citrate lyase inhibitor and a mitochondrial respiratory chain inhibitor, creating powerful but easily conflated metabolic phenotypes. This article presents a causal assay framework that separates lipid-biosynthesis effects from respiratory-chain blockade and translates the original Streptomyces findings into better experimental decisions.

• SGC-CBP30 in CREBBP/EP300 Bromodomain Research

  2026-08-19

  Use SGC-CBP30 as a selective mechanistic probe for CREBBP/EP300-dependent transcription, from chromatin occupancy and FRAP assays to TGF-β/SMAD3-driven lung adenocarcinoma models. Its biochemical potency and cellular activity support focused epigenetics research while preserving the need for dose, vehicle, and pathway controls.

• Diclofenac in Intestinal Organoid Research

  2026-08-18

  Use Diclofenac as a mechanistic COX perturbation tool while human iPSC-derived intestinal organoids add clinically relevant metabolism, transport, and epithelial-barrier context. This workflow connects cyclooxygenase inhibition assay design with pharmacokinetic profiling and inflammation signaling pathway analysis.

• Boc-D-FMK: From Caspase Blockade to Translation

  2026-08-18

  Boc-D-FMK is more than a broad-spectrum apoptosis probe: it can help translational researchers separate caspase-dependent cell death from inflammatory and fibrotic phenotypes. This article examines its mechanistic value, assay strategy, model selection, limitations, and opportunities for stronger causal evidence.

• ORAI2 Drives Early Postirradiation Salivary Fibrosis

  2026-08-17

  The reference study identifies ORAI2-mediated store-operated calcium entry as an early driver of radiation-induced salivary gland fibrosis and defines an ORAI2/JNK/NFAT1/TGF-β1 signaling axis. Its results connect calcium influx to fibrotic remodeling and suggest that pathway-level inhibition may help preserve salivary function, while also highlighting the limits of translating pharmacologic findings directly to patients.

• InstaBlue Protein Stain Solution: Practical Gel Guide

  2026-08-17

  InstaBlue Protein Stain Solution provides rapid Coomassie-based visualization of protein bands in polyacrylamide gels without fixation, washing, or destaining. It is suited to routine protein electrophoresis analysis and mass spectrometry workflows, but it should not replace a validated quantitative assay or protocols that require fixed gels or non-Coomassie chemistries.

• Novobiocin Sodium: Applied Research Workflows

  2026-08-16

  Novobiocin Sodium combines a defined DNA gyrase–focused antibacterial mechanism with practical value in DNA damage, viability, resistance, and exploratory antiparasitic assays. This guide translates the reference study into controlled workflows, assay design choices, and troubleshooting steps while separating established evidence from proposed applications.

• HBV G1896A, ER Stress, and HCC Glycolysis

  2026-08-15

  The reference study identifies a mechanistic link between the HBV precore G1896A mutation, PERK–ATF4 endoplasmic reticulum stress signaling, and PFKFB3-driven aerobic glycolysis in hepatocellular carcinoma. Its rescue and in vivo experiments suggest that the ATF4–PFKFB3 axis contributes to mutation-associated tumor growth, invasion, and metastasis, while also illustrating how phosphorylation-sensitive pathway measurements should be protected during sample handling.

• From Reporter Signal to Smarter mRNA Delivery

  2026-08-14

  A mechanistic and translational framework for using chemically optimized Firefly Luciferase mRNA to distinguish transcript performance from delivery biology, informed by recent work on spatially controlled mRNA delivery.

• YM 58483 (BTP2): From SOCE to Fibrosis

  2026-08-14

  YM 58483, also called BTP2, is a SOCE blocker that connects calcium-entry pharmacology with immune and radiation-induced fibrosis research. This article translates the ORAI2/JNK/NFAT1 findings into practical assay decisions while clarifying what BTP2 can—and cannot—prove mechanistically.

• SB203580: Translating p38 MAPK Insight into Action

  2026-08-13

  A translational framework for using SB203580 to test p38 MAPK-dependent inflammation, connect oral–pulmonary disease mechanisms, and design more decisive pathway-validation studies.

• Boc-D-FMK Workflows for Apoptosis Research

  2026-08-13

  Boc-D-FMK provides a practical way to suppress activated-caspase activity while separating apoptosis from inflammatory and fibrotic readouts. This guide translates product specifications into reproducible cell and animal workflows, with assay controls inspired by a hepatic stellate-cell fibrosis study.

• HDAC Inhibition Reverses EBV-Driven NPC Dedifferentiation

  2026-08-12

  The reference study identifies an epigenetic mechanism by which EBV LMP1 drives dedifferentiation and stem-like plasticity in nasopharyngeal carcinoma. It shows that HDAC inhibition restores CEBPA expression and reverses this state in xenograft models, providing a mechanistic rationale for differentiation-oriented treatment of a solid tumor.

• Caspase-8 Inhibition and Shared Caspase Specificity

  2026-08-12

  Bourne and colleagues developed an LESD-based peptide inhibitor derived from the IL-18 cleavage sequence that preferentially inhibits caspase-8, while revealing unexpected overlap between inflammatory and apoptotic initiator caspases. Their standardized comparisons also showed that VX-765, commonly used to inhibit caspases-1 and -4, inhibits caspase-8 at micromolar potency, an important consideration for interpreting caspase-targeted experiments.

• JNK-IN-7 for Reliable Apoptosis Assays

  2026-08-11

  Learn how JNK-IN-7 (SKU A3519) can improve mechanistic interpretation of cell viability, proliferation, and apoptosis experiments by selectively inhibiting JNK1, JNK2, and JNK3. This scenario-based guide covers assay design, formulation, controls, data interpretation, and practical product selection.

16685 records 1/1113 page Next 12345 下5页 Last page